{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:22Z","timestamp":1793598202108,"version":"4.5.0"},"reference-count":10,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"unspecified","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030719","name":"National Institute of Health Sciences","doi-asserted-by":"publisher","award":["R01DK24092-34"],"award-info":[{"award-number":["R01DK24092-34"]}],"id":[{"id":"10.13039\/100030719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>To compare carotid intima\u2013media thickness (cIMT) and liver fat content in subjects who maintained good glycemic control for 6 years on initial triple therapy with metformin\/exenatide\/pioglitazone versus sequential add-on therapy with metformin followed with glipizide and basal insulin in subjects with new-onset diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>Liver fat content and cIMT were compared among patients with T2DM who received initial triple therapy with metformin\/pioglitazone\/exenatide (n=29) versus metformin, followed by stepwise addition of glipizide and then insulin glargine (n=26) and who maintained HbA1c&lt;6.5% for 6 years in Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 years in subjects receiving initial triple therapy with metformin\/pioglitazone\/exenatide and subjects receiving sequential addition of metformin followed by glipizide and insulin glargine had a mean HbA1c of 5.7% vs 6.0%, respectively, p=NS. Nonetheless, subjects receiving sequential add-on therapy experienced a greater increase in cIMT and manifested greater liver fat content and fibrosis than subjects receiving initial triple therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Including pioglitazone plus exenatide in the glucose-lowering regimen slows the progression of cIMT and was associated with lower hepatic fat content and fibrosis compared with subjects receiving sequential add-on therapy without pioglitazone and exenatide despite comparable optimal glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01107717\">NCT01107717<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-004981","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T05:00:15Z","timestamp":1745730015000},"page":"e004981","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct01107717","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01107717","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4556-1787","authenticated-orcid":false,"given":"Muhammad","family":"Abdul-Ghani","sequence":"first","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtiss","family":"Puckett","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Abdelgani","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Merovci","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lavrynenko","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Adams","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Triplitt","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-1724","authenticated-orcid":false,"given":"Ralph A","family":"DeFronzo","sequence":"additional","affiliation":[{"name":"Diabetes Division, UT Health San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"2025073112261384000_13.2.e004981.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025073112261384000_13.2.e004981.2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"2025073112261384000_13.2.e004981.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S010"},{"key":"2025073112261384000_13.2.e004981.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930"},{"key":"2025073112261384000_13.2.e004981.5","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2020.0140"},{"key":"2025073112261384000_13.2.e004981.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8"},{"key":"2025073112261384000_13.2.e004981.7","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774"},{"key":"2025073112261384000_13.2.e004981.8","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0978"},{"key":"2025073112261384000_13.2.e004981.9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12417"},{"key":"2025073112261384000_13.2.e004981.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010949"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-004981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:26:25Z","timestamp":1753989985000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-004981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,27]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjdrc-2025-004981"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-004981","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}